Inovio Pharmaceuticals (NASDAQ:INO) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.

Several other equities analysts have also commented on INO. Zacks Investment Research upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 3rd. HC Wainwright set a $13.00 price objective on Inovio Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 7th. ValuEngine upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, September 5th. Finally, Maxim Group reiterated a “buy” rating and set a $8.00 price objective on shares of Inovio Pharmaceuticals in a research report on Thursday, August 16th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Inovio Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $11.25.

Shares of Inovio Pharmaceuticals stock opened at $5.25 on Thursday. The stock has a market cap of $462.06 million, a PE ratio of -4.82 and a beta of 1.83. Inovio Pharmaceuticals has a 12 month low of $3.64 and a 12 month high of $7.00.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.27. The firm had revenue of $24.45 million for the quarter, compared to analyst estimates of $2.13 million. Inovio Pharmaceuticals had a negative return on equity of 71.53% and a negative net margin of 252.95%. sell-side analysts anticipate that Inovio Pharmaceuticals will post -1.07 earnings per share for the current fiscal year.

In related news, CEO Jong Joseph Kim sold 49,060 shares of the firm’s stock in a transaction that occurred on Wednesday, September 12th. The stock was sold at an average price of $5.37, for a total transaction of $263,452.20. Following the transaction, the chief executive officer now directly owns 2,357,554 shares in the company, valued at approximately $12,660,064.98. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Peter Kies sold 35,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 10th. The stock was sold at an average price of $4.44, for a total value of $155,400.00. Following the transaction, the chief financial officer now owns 97,088 shares in the company, valued at $431,070.72. The disclosure for this sale can be found here. 9.40% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Levin Capital Strategies L.P. grew its position in Inovio Pharmaceuticals by 80.5% during the 2nd quarter. Levin Capital Strategies L.P. now owns 37,000 shares of the biopharmaceutical company’s stock worth $145,000 after acquiring an additional 16,500 shares during the last quarter. Emerald Advisers Inc. PA bought a new position in Inovio Pharmaceuticals during the 2nd quarter worth approximately $228,000. Connor Clark & Lunn Investment Management Ltd. grew its position in Inovio Pharmaceuticals by 50.2% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 101,225 shares of the biopharmaceutical company’s stock worth $397,000 after acquiring an additional 33,825 shares during the last quarter. Bank of America Corp DE grew its position in Inovio Pharmaceuticals by 36.6% during the 2nd quarter. Bank of America Corp DE now owns 114,660 shares of the biopharmaceutical company’s stock worth $449,000 after acquiring an additional 30,740 shares during the last quarter. Finally, New York State Common Retirement Fund grew its position in Inovio Pharmaceuticals by 14.3% during the 1st quarter. New York State Common Retirement Fund now owns 146,243 shares of the biopharmaceutical company’s stock worth $689,000 after acquiring an additional 18,300 shares during the last quarter. Institutional investors and hedge funds own 31.52% of the company’s stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.

Read More: Fundamental Analysis

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.